Bank of New York Mellon
CLSD

Bank of New York Mellon’s Clearside Biomedical CLSD Stock Holding History

Bank of New York Mellon’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,968
Closed -$34.5K – 4189
2023
Q4 		$34.5K Hold
1,968
– – ﹤0.01% 4189
2023
Q3 		$25.7K Hold
1,968
– – ﹤0.01% 4227
2023
Q2 		$33.1K Hold
1,968
– – ﹤0.01% 4232
2023
Q1 		$30.7K Hold
1,968
– – ﹤0.01% 4261
2022
Q4 		$33.1K Hold
1,968
– – ﹤0.01% 4292
2022
Q3 		$33K Hold
1,968
– – ﹤0.01% 4384
2022
Q2 		$43K Sell
1,968
-85
-4% -$2.06K ﹤0.01% 4378
2022
Q1 		$71K Hold
2,053
– – ﹤0.01% 4472
2021
Q4 		$85K Hold
2,053
– – ﹤0.01% 4424
2021
Q3 		$185K Buy
2,053
+779
+61% +$68.8K ﹤0.01% 4236
2021
Q2 		$93K Hold
1,274
– – ﹤0.01% 4229
2021
Q1 		$47K Sell
1,274
-127
-9% -$6.38K ﹤0.01% 4270
2020
Q4 		$58K Hold
1,401
– – ﹤0.01% 4138
2020
Q3 		$32K Hold
1,401
– – ﹤0.01% 4064
2020
Q2 		$39K Hold
1,401
– – ﹤0.01% 4008
2020
Q1 		$36K Hold
1,401
– – ﹤0.01% 4008
2019
Q4 		$61K Hold
1,401
– – ﹤0.01% 4085
2019
Q3 		$13K Sell
1,401
-1,815
-56% -$26K ﹤0.01% 4202
2019
Q2 		$47K Sell
3,216
-4,137
-56% -$73.8K ﹤0.01% 4126
2019
Q1 		$152K Sell
7,353
-112
-2% -$2.22K ﹤0.01% 3937
2018
Q4 		$120K Buy
7,465
+1,844
+33% +$86.5K ﹤0.01% 3935
2018
Q3 		$519K Buy
5,621
+253
+5% +$30.1K ﹤0.01% 3634
2018
Q2 		$861K Sell
5,368
-4,552
-46% -$767K ﹤0.01% 3330
2018
Q1 		$1.6M Buy
9,920
+3,872
+64% +$472K ﹤0.01% 2939
2017
Q4 		$636K Sell
6,048
-19
-0.3% -$2.04K ﹤0.01% 3498
2017
Q3 		$795K Sell
6,067
-166
-3% -$20.3K ﹤0.01% 3352
2017
Q2 		$852K Buy
6,233
+3,911
+168% +$470K ﹤0.01% 3341
2017
Q1 		$277K Buy
2,322
+227
+11% +$26.8K ﹤0.01% 3773
2016
Q4 		$281K Buy
2,095
+982
+88% +$246K ﹤0.01% 3802
2016
Q3 		$289K Buy
+1,113
New +$136K ﹤0.01% 3771

Other funds holding CLSD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon's CLSD Position: Q1 2024 in Review

Bank of New York Mellon sold out of Clearside Biomedical (CLSD) in Q1 2024, closing a stake of 1,968 shares — an estimated $34.5K sold.

Bank of New York Mellon first reported a position in CLSD in Q3 2016 and held it in 30 quarters. The position peaked at $1.6M in Q1 2018. 51 funds tracked by Wall St. Rank hold CLSD as of Q1 2024.

  • Bank of New York Mellon reported no remaining Clearside Biomedical position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 1,968 Clearside Biomedical shares in Q1 2024, an estimated $34.5K.
  • Bank of New York Mellon first reported a position in Clearside Biomedical in Q3 2016 and held it in 30 quarters.
  • Bank of New York Mellon's Clearside Biomedical position peaked at $1.6M in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.